Candor on gene therapy, Abiomed is warned, & BTK success in MS
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning! Today, cell and gene therapy executives describe how they’re handling their sector’s contraction, we talk about how regulators are cracking down on clinical decision support software, and we look at some impressive BTK data in multiple sclerosis from Roche.
Read Original Article: Candor on gene therapy, Abiomed is warned, & BTK success in MS »
